P/E ratio for Enanta Pharmaceuticals (ENTA)

P/E ratio history for Enanta Pharmaceuticals from 2013 to 2023

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
AbbVie ABBV	46.9	-5,879.64%	🇺🇸 USA
Johnson & Johnson JNJ	10.5	-1,396.27%	🇺🇸 USA
Vertex Pharmaceuticals VRTX	32.7	-4,128.58%	🇺🇸 USA
Merck MRK	52.8	-6,610.94%	🇺🇸 USA
Bristol-Myers Squibb BMY	14.4	-1,870.72%	🇺🇸 USA
Novartis NVS	26.7	-3,386.35%	🇨🇭 Switzerland

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.